Founded in 2012, and listed in 2022 in HKEX (Stock Code: 2172.HK.). MicroPort® NeuroTech has been at the forefront of neurovascular care. Our comprehensive neuro-interventional devices portfolio encompasses three key domains: hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke.
With 196+ authorized patents and a presence in over 2800 hospitals, our commitment to innovation is resolute. Our products facilitate more than 100 cerebrovascular stenting procedures daily.
At MicroPort® NeuroTech, our mission is to deliver accessible, top-quality, and comprehensive solutions for stroke patients globally. We are dedicated to pushing the boundaries of neuro-interventional care, aiming for better and longer lives for patients around the world.